Histone methyltransferases as a new target for the epigenetic action by vorinostat DOI
Varvara Maksimova,

Julia Makus,

Valeriia Popova

et al.

Биохимия, Journal Year: 2023, Volume and Issue: 88(7), P. 1191 - 1203

Published: Dec. 15, 2023

Aberrant methylation and acetylation of histones are characteristic changes in the system epigenetic regulation gene expression accompanying process malignant transformation cell. Vorinostat is modulator that actively used clinical oncology practice. The antitumor activity vorinostat considered to be associated with only inhibition histone deacetylases. effects this drug on have not been sufficiently studied. Using HeLa TI test system, which allows evaluating integral effect epigenetically active compounds by activating reporter GFP, knockdown genes small interfering RNAs, we showed inhibitory directed at HDAC1, but also EZH2, SUV39H1, SUV39H2, SUV420H1. Western blotting, ability suppress enzymes SUV39H1/2, SUV420H1 was confirmed and, addition, its inhibit SUV420H2 DOT1L revealed. data obtained expand understanding demonstrate need for a large-scale analysis relation other enzymes. A detailed mechanism action will contribute more adequate use treatment tumors an aberrant profile.

Language: Английский

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies DOI Creative Commons
Bohan Wang, Yachong Liu, Zhibin Liao

et al.

Experimental Hematology and Oncology, Journal Year: 2023, Volume and Issue: 12(1)

Published: June 2, 2023

Abstract Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation genetic and epigenetic changes closely related to occurrence development HCC. Enhancer zeste homolog 2 (EZH2, a histone methyltransferase) suggested be one principal factors that mediates oncogenesis by acting as driver alternation. Recent studies show EZH2 widely involved in proliferation metastasis HCC cells. In this review, functions progression, role tumor immunity application EZH2-related inhibitors therapy are summarized.

Language: Английский

Citations

27
The Emerging Role of Natural Products in Cancer Treatment DOI
Sumit Ghosh, Sanjib Das, Krishnendu Sinha

et al.

Archives of Toxicology, Journal Year: 2024, Volume and Issue: 98(8), P. 2353 - 2391

Published: May 25, 2024

Language: Английский

Citations

10
Therapeutic targeting of TGF‐β in lung cancer DOI Creative Commons

Sajjad Aftabi,

Amir Barzegar Behrooz, Marco Cordani

et al.

FEBS Journal, Journal Year: 2024, Volume and Issue: unknown

Published: July 31, 2024

Transforming growth factor‐β (TGF‐β) plays a complex role in lung cancer pathophysiology, initially acting as tumor suppressor by inhibiting early‐stage growth. However, its evolves the advanced stages of disease, where it contributes to progression not directly promoting cell proliferation but enhancing epithelial–mesenchymal transition (EMT) and creating conducive microenvironment. While EMT is typically associated with enhanced migratory invasive capabilities rather than per se , TGF‐β's influence on this process facilitates dynamics metastasis. Additionally, TGF‐β impacts microenvironment interacting immune cells, influenced genetic epigenetic changes within cells. This interaction highlights evasion chemoresistance, further complicating therapy. review provides critical overview recent findings involvement cancer, contribution modulation response. Despite considerable challenges encountered clinical trials development new treatments targeting pathway, necessity for continued, in‐depth investigation into roles TGF‐β. A deeper comprehension these may lead novel, targeted therapies cancer. intricate behavior signaling tumors previous challenges, research could yield innovative treatment strategies.

Language: Английский

Citations

7
Exosomal RNAs and EZH2: unraveling the molecular dialogue driving tumor progression DOI
Ahmed Hussein Zwamel, Adnan Ahmad, Farag M. A. Altalbawy

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(4)

Published: March 12, 2025

Language: Английский

Citations

0
Significance of extracellular vesicles in orchestration of immune responses in Mycobacterium tuberculosis infection DOI Creative Commons
Shamila D. Alipoor, Daniel Elieh Ali Komi

Frontiers in Cellular and Infection Microbiology, Journal Year: 2024, Volume and Issue: 14

Published: May 21, 2024

Mycobacterium tuberculosis (M.tb) , the causative agent of Tuberculosis, is an intracellular bacterium well known for its ability to subvert host energy and metabolic pathways maintain survival. For this purpose, bacteria utilize various mechanisms which extracellular vehicles (EVs) related attracted more attention. EVs are nanosized particles that released by almost all cell types containing active biomolecules from origin can target bioactive in recipient cells upon uptake. It hypothesized M.tb dictates processes EV biogenesis pathways, selectively incorporating molecules into direct immune responses favor. During infection with Mtb both mycobacteria release EVs. The composition these varies over time, influenced physiological nutritional state environment. Additionally, different populations contribute differently pathogenesis disease at stages illness participating a complex interplay between pathogens. These interactions ultimately influence outcomes. However, precise roles pathogenicity outcomes remain be fully elucidated. In review, we explored properties function context within microenvironment discussed their capacity as novel therapeutic strategy combat tuberculosis.

Language: Английский

Citations

3
Cuproptosis-related ceRNA axis triggers cell proliferation and cell cycle through CBX2 in lung adenocarcinoma DOI Creative Commons
Jiang Wu, Guang Fu, Chao Luo

et al.

BMC Pulmonary Medicine, Journal Year: 2024, Volume and Issue: 24(1)

Published: Feb. 14, 2024

Lung adenocarcinoma (LUAD) has high morbidity and mortality. Despite substantial advances in treatment, the prognosis of patients with LUAD remains unfavorable. The ceRNA axis been reported to play an important role pathogenesis LUAD. In addition, cuproptosis is considered factor tumorigenesis. expression CBX2 associated development multiple tumors, including However, precise molecular mechanisms through which cuproptosis-related network regulates remain unclear.

Language: Английский

Citations

2
Histone Methyltransferases as a New Target for Epigenetic Action of Vorinostat DOI Creative Commons
Varvara Maksimova,

Julia Makus,

Valeriia Popova

et al.

Biochemistry (Moscow), Journal Year: 2023, Volume and Issue: 88(7), P. 968 - 978

Published: July 1, 2023

Epigenetic genome regulation during malignant cell transformation is characterized by the aberrant methylation and acetylation of histones. Vorinostat (SAHA) an epigenetic modulator actively used in clinical oncology. The antitumor activity vorinostat commonly believed to be associated with inhibition histone deacetylases, while impact this drug on has been poorly studied. Using HeLa TI cells as a test system allowing evaluation effect epigenetically active compounds from expression GFP reporter gene knockdown small interfering RNAs, we showed that not only suppressed HDAC1, but also reduced EZH2, SUV39H1, SUV39H2, SUV420H1. ability suppress SUV39H1/2, SUV420H1 was confirmed Western blotting. downregulated SUV420H2 DOT1L enzymes. data obtained expand our understanding effects demonstrate need for large-scale analysis its toward other enzymes involved regulation. Elucidation mechanism underlying action will contribute more proper use treatment tumors profile.

Language: Английский

Citations

5
The bidirectional interplay between ncRNAs and methylation modifications in gastrointestinal tumors DOI Creative Commons
Minyu Kong, Yu Xiao, Wenzhi Guo

et al.

International Journal of Biological Sciences, Journal Year: 2023, Volume and Issue: 19(15), P. 4834 - 4848

Published: Jan. 1, 2023

The aberrant expression of methylation and ncRNAs, two crucial regulators epigenetic modifications, has been widely demonstrated in cancer.The complex interplay between them is essential promoting malignant phenotype, poor prognosis, drug resistance GI tumors (including esophageal, gastric, colorectal, liver, pancreatic cancers).Therefore, we summarize the interrelation process ncRNAs modifications tumors, including detailed mechanism enzyme regulation molecular correlation interactions clinical features tumors.Finally, discuss potential value diagnosis therapy.

Language: Английский

Citations

4
GSK-126 Enhances All-Trans-Retinoic Acid (ATRA) Response in Hepatocellular Carcinoma (HCC) by Upregulating RARG Expression DOI Creative Commons
Z. Q. Liu,

Yongxia Zheng

Discovery Medicine, Journal Year: 2024, Volume and Issue: 36(184), P. 1041 - 1041

Published: Jan. 1, 2024

Hepatocellular carcinoma (HCC) stands out as one of the most prevalent malignant tumors globally. The combination all-trans-retinoic acid (ATRA) with FOLFOX chemotherapy has shown promise in enhancing prognosis HCC patients. ATRA, serving a chemosensitizing agent, presents novel possibilities for therapeutic applications. Nevertheless, responsiveness cells to ATRA varies. epigenetic modifier-GSK-126 is currently under investigation potential antitumor drug. Our aim explore molecular mechanisms underlying diverse sensitivity patients and propose new regimen. This research aims lay groundwork personalized medication approaches individuals HCC.

Language: Английский

Citations

1
EZH2: A Critical Competing Endogenous RNA in Cancer Research - A Scoping Review DOI Creative Commons
Sadra Salehi-Mazandarani, Sharareh Mahmoudian-Hamedani, Ziba Farajzadegan

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: April 22, 2024

Abstract In recent years, research on the competing endogenous RNAs (ceRNAs) in cancer is full swing. These investigations are discovering importance of critical progression. Enhancer zeste 2 polycomb repressive complex subunit ( EZH2 ) one these that has been identified as a potential therapeutic target many types cancer. Up to now, studies have conducted elucidate ceRNA role Due EZH2’s dual an oncogene and tumor suppressor cancer, more thorough exploration its functions may enhance clinical approaches treatment. current scoping review, we searched online databases including PubMed, Web Science, Scopus, Embase, Cochrane Library, Google Scholar identify experimentally-validated axes human cancers. We 62 unique consisting 30 microRNAs (miRNAs), 31 long non-coding (lncRNAs), 9 messenger (mRNAs), 14 circular (circRNAs). Notably, SPRY4-IT1 - miR-101-3p XIST were recurrent observed multiple types. Among most frequent miRNAs miR-101-3p, miR-144-3p, miR-124-3p, ceRNAs , SNHG6 HOXA11-AS MALAT1 TUG1 emerged competitors for miRNA binding. This review highlights prevalence diversity -containing suggesting their targets. Future should delve deeper into functional significance assess applicability.

Language: Английский

Citations

0